Melanotan I vs Melanotan II: One Approved Medicine, One Grey-Market Agonist

One letter separates their names, and almost everything separates their pharmacology. Melanotan I is a medicine with a marketing authorisation, a brand name, and a defined orphan indication; Melanotan II is the compound people usually mean when they type “melanotan” into a search bar — the unapproved one pursued for tan and libido alike.¹²¹⁴ The two are routinely conflated, sold side by side, and treated as a dosage choice between weaker and stronger. They are nothing of the sort.

Why are these two peptides so often confused?

Both are derived from alpha-melanocyte-stimulating hormone (alpha-MSH), the endogenous melanocortin peptide that drives melanogenesis through the melanocortin-1 receptor (MC1R). Both emerged from the same broad line of academic work on “sunless” pigmentation, which is widely credited to melanocortin research groups in the United States.⁸ The shared lineage, the near-identical names, and a grey market indifferent to the distinction did the rest. But the molecules diverged early. Melanotan I — afamelanotide — is described in the literature as a modified, essentially linear alpha-MSH analogue carrying substitutions that resist enzymatic breakdown while preserving the parent peptide’s relative preference for MC1R.⁴⁸ Melanotan II is a smaller cyclic peptide: a lactam ring constrains its backbone, which is generally reported to raise potency¹⁶ and, critically, to broaden its reach across the melanocortin receptor family.¹⁸¹⁵

How do their structures change what they do?

That ring is much of the story. Cyclisation appears to lock Melanotan II into a conformation that activates not only MC1R (pigmentation) but also MC3R and MC4R, the central receptors associated with energy balance, sexual function and autonomic tone.¹⁸¹⁷ MC4R activation is the commonly cited explanation for why the peptide is reported to produce erections and nausea¹²¹¹ — effects that have nothing to do with tanning and everything to do with promiscuous receptor binding. Notably, the cyclic melanocortin scaffold of this class was the acknowledged starting point for bremelanotide, an MC4R-leaning agonist later approved for hypoactive sexual desire disorder¹⁸, which underlines how much of this pharmacology lives off-target from pigment. Melanotan I, by contrast, is generally characterised as staying closer to the native ligand’s profile: comparatively more selective for MC1R, and advanced in clinical development precisely because that relative selectivity narrows its effects toward the skin.²⁴

Head-to-head: the two compounds share an origin and a target receptor but diverge sharply on selectivity, regulatory standing and evidence quality.

Which one is actually approved — and as what?

Only Melanotan I. As afamelanotide, it carries a marketing authorisation under the brand Scenesse: it was authorised in the European Union in the mid-2010s and subsequently in the United States⁶³, in both cases for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP), a rare inherited disorder in which sunlight triggers severe pain.⁵⁷ In the controlled trials that supported that authorisation, the Scenesse product was reported to increase pain-free light exposure in EPP patients by inducing eumelanin without ultraviolet light³⁶¹ — an efficacy outcome that belongs to the licensed implant studied in those trials, not to a vial of reference material. That medicine is a controlled-release implant placed under the skin by a clinician in a specialist setting — a tightly defined clinical product. It is emphatically not the vial form sold as a reference material. Melanotan II has no such status: it has never completed the development pathway and is approved by no regulator, which is why public-health authorities have repeatedly warned about products sold under the “melanotan” name.¹⁰¹¹

~1 in 100,000 roughly the order of magnitude of erythropoietic protoporphyria’s rarity — the orphan indication for which afamelanotide, but not Melanotan II, is approved.¹⁵

What does the safety record honestly show?

Here the comparison must be told plainly. Melanotan II’s adverse-event literature is real and reasonably consistent: priapism (prolonged, sometimes painful erections), nausea and flushing¹²¹¹, and dermatological effects including darkening and, more troublingly, the rapid appearance of new or changing melanocytic naevi.¹⁴ Published case reports describe atypical naevi and altered moles emerging within weeks of reported use.¹⁴¹³ A melanoma association has been raised — but this is where intellectual honesty matters. The signal is confounded: people using Melanotan II for tanning typically combine it with aggressive ultraviolet exposure, the single best-established melanoma risk factor.¹⁴ Disentangling peptide from sunbed is not possible from scattered case reports, and the balance of evidence is generally read as pointing to the heavy UV behaviour these users seek being a more plausible driver than the peptide acting alone. What can be said cleanly is that Melanotan II has not been characterised to the standard of a licensed drug, that grey-market samples have been reported to vary in identity and purity¹⁶¹⁰, and that it is associated with harms which comparatively selective MC1R activation would not predict.¹¹¹⁰

One is a characterised, comparatively selective, approved medicine delivered by a physician; the other is an unapproved broad agonist whose very lack of selectivity is both its grey-market appeal and its catalogue of harms.

The deeper lesson for anyone comparing them is that “stronger” is the wrong axis. Melanotan II is not simply a more potent Melanotan I; it is a different pharmacological object — a non-selective agonist whose extra activity is precisely what is invoked to explain priapism, nausea and the other off-target effects.¹²¹⁸ Selectivity, not raw potency, is the meaningful dividing line, and it tracks the regulatory verdict: the comparatively selective molecule earned approval; the promiscuous one did not.²⁹

Both compounds appear in the Condor Research catalogue strictly as research reference materials for in-vitro and laboratory investigation — not for human use, tanning, or any therapeutic application. Neither vial is the licensed medicine: Scenesse is a physician-placed implant supplied through regulated clinical channels and is not what is offered here. Each reference material is provided with a certificate of analysis documenting identity and purity by HPLC and mass spectrometry¹⁶, so investigators can verify exactly what is in the vial before any characterisation work begins.